2.36
前日終値:
$1.80
開ける:
$2.05
24時間の取引高:
10.66M
Relative Volume:
6.06
時価総額:
$274.42M
収益:
$6.65M
当期純損益:
$-136.32M
株価収益率:
-2.0563
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+81.54%
1か月 パフォーマンス:
+93.44%
6か月 パフォーマンス:
+116.51%
1年 パフォーマンス:
+101.71%
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics Inc
|
2.36 | 209.31M | 6.65M | -136.32M | -112.04M | -1.1477 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com
Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com Canada
FDA picks Fate's lupus cell therapy for manufacturing-readiness pilot - Stock Titan
Fate Therapeutics Selected For U.S. FDA Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program To Support Manufacturing Readiness Of Ft819 - TradingView
Fate Therapeutics Selected for U.S. FDA Chemistry, - GlobeNewswire
Off-the-shelf CAR-T studies target lupus, diabetes and cancer - Stock Titan
Fate Therapeutics announces three presentations at the 2026 ASGCT annual meeting highlighting off-the-shelf CAR T-cell therapy pipeline for cancer and autoimmune diseases - marketscreener.com
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - Yahoo Finance UK
H.C. Wainwright raises Fate Therapeutics price target to $7 on SLE data - Investing.com Canada
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $7 - Moomoo
FATE Stock Rises As Fate Therapeutics Showcases FT839 CAR T Data - StocksToTrade
MSN Money - MSN
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Fate hire gets 30,200 shares in Nasdaq-compliant award - Stock Titan
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
CAR-T Cell Therapy Market Will Generate Booming Growth Opportunities to 2030 | Novartis, Johnson & Johnson Services, Mustang, Sorrento Therapeutics, Fate Therapeutics etc. - industrytoday.co.uk
Single-dose FT819 data in 10 lupus patients heads to rheumatology meeting - Stock Titan
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting - ChartMill
Fate Therapeutics (NASDAQ: FATE) sets 2026 proxy votes and 7M-share plan boost - Stock Titan
Fate Therapeutics | DEF 14A: Definitive information statements - Moomoo
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart
Redmile (NASDAQ: FATE) corrects cash-settled swap reference price - Stock Titan
iPSC-Derived NK Cells Pipeline Set to Transform Cancer - openPR.com
Redmile (NASDAQ: FATE) shifts stake to SPV in internal reorg - Stock Titan
FATE Financials: Income Statement, Balance Sheet & Cash Flow | Fate Therapeutic - Stock Titan
Fate Therapeutics (FATE) Stock: Why Market Expansion (Breakdown Watch) 2026-04-20Social Buzz - UBND thành phố Hải Phòng
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases - marketscreener.com
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t - Sahm
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Announces Data Presentation Of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate For The Broad Treatment Of Hematological Malignancies And Autoimmune Diseases Without The Need For Conditioning Chemotherapy - marketscreener.com
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference - MarketBeat
NK Cell Therapy Market Is Booming Rapidly with Strong Demand - openPR.com
Aug Wrap: Is Fate Therapeutics Inc part of any ETFDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenueTrend Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Fate Therapeutics Inc stock (US3025491025): Is its iPSC platform strong enough to unlock biotech ups - AD HOC NEWS
Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement - AD HOC NEWS
FATE Q4 2025 Earnings: Fate Therapeutics Inc. posts narrow EPS beat, no revenue reportedElite Trading Signals - UBND thành phố Hải Phòng
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences - GlobeNewswire
Fate Therapeutics plans appearances at 5 investor conferences by June - Stock Titan
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Fate Therapeutics Announces New Employee Inducement Award - National Today
Fate Therapeutics Inc (F6T.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Street Watch: Is Fate Therapeutics Inc subject to activist investor interest2026 Rallies & Weekly Breakout Watchlists - baoquankhu1.vn
FATE Should I Buy - Intellectia AI
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Scalable Biotech Manufacturing Unlocks a $14B Market - Sahm
Vanguard (FATE) reports 0 shares after internal realignment - Stock Titan
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):